The 64th ASH (American Society of Hematology) Annual Meeting & Exposition is being held in New Orleans Dec. 10 – 13. I went to their website (link below) and searched for Leronlimab. I did not expect any hits and did not get any. I then searched for Cytodyn and got 6 hits, all of which were noted in the Disclosures at the bottom of 6 poster abstracts where Dr. Mehrdad Abedi was a co-author. This was the disclosure:

Abedi: Cytodyn: Current equity holder in publicly-traded company; Celgene: Consultancy, Speakers Bureau; Orca Bio: Research Funding; Kite, a Gilead Company: Speakers Bureau; AbbieVie: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau.

He is with the Department of Internal Medicine, Division of Cellular Therapy, Bone Marrow Transplantation and Malignant Hematology, University of California Davis School of Medicine, Sacramento, CA.

This is what is noted about him on their website:

Dr. Abedi's clinical interest is in the area of bone marrow transplantation and in the treatment of refractory/relapsed hematological malignancies and genetic disease. He is also interested in using cellular therapy for treatment of a variety of medical disorders.
Dr. Abedi's basic science research interest is in the area of hematopoietic stem cells and novel models of bone marrow transplantation, and also gene and cellular therapy.

https://health.ucdavis.edu/cancer/team/1329/m...acramento/

Link for ASH meeting

https://www.hematology.org/Meetings/Annual-Meeting

Nice to have a doctor with his pedigree as a stockholder.